Condition
Visceral (Hyper)Sensitivity
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 2 (1)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03462966Phase 2TerminatedPrimary
Rifaximin on Visceral Hypersensitivity
NCT02358564Not ApplicableCompleted
Gut Permeability, Sensitivity and Symptomatology
NCT02924493Not ApplicableCompleted
Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome
NCT03224494Not ApplicableUnknown
Evaluation of Bowel Sensitivity Threshold in IBS Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag
NCT00726817Not ApplicableCompletedPrimary
The Effects of Butyrate Enemas on Visceral Perception
Showing all 5 trials